The warning raised by Professor Booth that the United Kingdom risks falling into the European “relegation zone” for prostate cancer survival highlights a reality the British healthcare system can no longer afford to ignore: without a structured early-detection programme, the NHS will inevitably continue diagnosing too many prostate cancers at advanced stages, when therapeutic options become significantly more limited.

































































































